News
Initialement axées sur les soins de santé, les solutions Imprivata permettent un accès clinique rapide et sécurisé aux services informatiques afin de soutenir le programme CaRE et en particulier le do ...
Most people living with spinal cord injury experience blood pressure instability, which represents a key unmet need EINDHOVEN, The Netherlands, Sept. 18, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V.
EUROAPI s'engage à réduire ses émissions absolues de gaz à effet de serre (GES) des Scopes 1 et 2 d'ici à 2030 de 42 %, par rapport à l'année de référence 2022. L'entreprise s'engage également à ...
Roche to acquire 89bio for US$14.50 per share in cash at closing, representing a total equity value of approximately US$2.4 billion. Stockholders would also receive a non-tradeable contingent value ...
September 18, 2025 - EUROAPI’s near-term science-based emission reduction targets have been approved by the Science Based Targets initiative (SBTi 1 ), confirming the company’s alignment with the ...
– 89bio to join the Roche Group as part of Roche’s Pharmaceuticals Division – ...
SHANGHAI, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in AI-driven Internet healthcare solutions, was recognized as an “Outstanding Growth Story ...
EssilorLuxottica and Meta build on their successful partnership with new AI glasses that offer a glimpse into the future. The two companies continue to grow their wearables lineup ...
Le partenariat EssilorLuxottica et Meta se poursuit avec de nouvelles lunettes avec IA qui préfigurent le futur Les deux groupes élargissent leur gamme de « wearables » avec de nouveaux produits ...
“Winning this award is a testament to our efforts in using AI to improve chronic disease management,” Dr. Xie said. “By ...
The DEXA-L, part of the DEXA Technology Platform, is a stand-alone device for anterior lumbar interbody fusion (ALIF) procedures and is the first of its kind in the world. It is the first spinal ...
SOUTH SAN FRANCISCO, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback